Neuren Pharmaceuticals company info

What does Neuren Pharmaceuticals do?
Neuren Pharmaceuticals (ASX:NEU) is an Australian-based pharmaceutical company that develops and commercialises new drugs for the treatment of central nervous system (CNS) disorders. The company's flagship asset is NNZ-2566, a drug candidate for the treatment of Fragile X syndrome, a rare genetic disorder that causes intellectual disability. Neuren is also developing a number of other drug candidates for the treatment of other CNS disorders, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. Neuren's operations are focused on the development and commercialization of new drugs for CNS disorders. The company has a number of drug candidates in clinical trials, and is also working on the development of new preclinical drug candidates.
Neuren Pharmaceuticals company media
Company Snapshot

Is Neuren Pharmaceuticals a public or private company?


How many people does Neuren Pharmaceuticals employ?


What sector is Neuren Pharmaceuticals in?

pie chart
Health Care

Where is the head office for Neuren Pharmaceuticals?

location pin
Head Office
Victoria, Australia

What year was Neuren Pharmaceuticals founded?

founded flag
Year Founded
What does Neuren Pharmaceuticals specialise in?
/Biotech /Pharmaceutical /Health /Medical /Medtech

What are the products and/or services of Neuren Pharmaceuticals?

Overview of Neuren Pharmaceuticals offerings
Developing Trofintide (NEP1492), an investigational drug for the treatment of Rett syndrome and Fragile X syndrome.
Developing NNZ-2566, an investigational drug for the treatment of Angelman syndrome.
Developing NNZ-529, an investigational drug for the treatment of Parkinson's disease.
Developing new drugs for the treatment of nervous system disorders.
Conducting clinical trials to evaluate the safety and efficacy of its investigational drugs.
Seeking regulatory approval for its investigational drugs.

Who is in the executive team of Neuren Pharmaceuticals?

Neuren Pharmaceuticals leadership team
  • Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
    Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
    CEO, MD & Executive Director
  • Ms. Lauren  Frazer C.A.
    Ms. Lauren Frazer C.A.
    CFO & Company Secretary
  • Mr. Lawrence  Glass BA (Biology)
    Mr. Lawrence Glass BA (Biology)
    Chief Science Officer
  • Mr. Gerry  Zhao
    Mr. Gerry Zhao
    Vice President of Corporate Development
  • Dr. Liza A. Squires M.D.
    Dr. Liza A. Squires M.D.
    Chief Medical Officer